UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
May 21, 2009
 
TRANSGENOMIC, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
  
000-30975
  
911789357
(State of Incorporation)
  
(Commission File Number)
  
(IRS Employer Identification
Number)
        

 
12325 Emmet Street, Omaha, Nebraska
  
68164
  
 
(Address of principal executive offices)
  
(Zip Code)
  

 
(402) 452-5400
(Registrant’s telephone number, including area code)
 
Not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
Item 5.02                      Departure of Director.
 
Frank Witney, a member of the Board of Directors of Transgenomic, Inc., has submitted his resignation from the Board effective May 20, 2009.  Mr. Witney’s resignation is due to his new role as President and Chief Executive Officer of Dionex.

 
SIGNATURES

 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated:  May 21, 2009
TRANSGENOMIC, INC.
 
 
 
 
By:
/s/ Debra A. Schneider
Debra A. Schneider
Chief Financial Officer